Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
350 participants
INTERVENTIONAL
2023-08-08
2028-08-08
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Genotype-phenotype Characterization Study on Genetic Diseases With Immune and Neurological Dysfunctions
NCT06235580
Functional Genomics of Rare Genetic Diseases: Realization of Innovative Tools With High Diagnostic Power
NCT04152876
Contribution of New Generation Oxford Nanopore-type High-throughput Sequencing in the Diagnostic Strategy of Neurogenetic Diseases.
NCT04621422
Identification of New FTLD Genes
NCT02363062
Investigational Biomarkers for Neurological Immune-related Adverse Events
NCT05969379
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Control cohort
Patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Collection of biological sample (blood and/or CSF)
Blood sample will be collected one time for each patient:
2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube
If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Collection of biological sample (blood and/or CSF)
Blood sample will be collected one time for each patient:
2 \*4ml of blood on dry tube 2 \*4ml of blood on EDTA tube
If cerebrospinal fluid (CSF) has been drawn for diagnosis, remaining sample available will be stored in the control cohort (1 ml).
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* patient with following disease: Parkinson's disease, Amyotrophic lateral sclerosis, Glioblastoma, cancer without neurological disease (pulmonary cancer, breast cancer, ovarian cancer, melanoma, thymoma), rheumatoid arthritis.
Exclusion Criteria
* patient with neurological disorder compatible with paraneoplastic neurological syndrome or auto-immune encephalitis
* patient under guardianship
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hospices Civils de Lyon
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Jerome Honnorat, Pr
Role: PRINCIPAL_INVESTIGATOR
Centre de référence des syndromes neurologiques paranéoplasiques et encéphalites auto-immunes, Lyon, France
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospices Civils de Lyon
Bron, , France
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
69HCL22_0275
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.